APA (7th ed.) Citation

Skljarevski, V., Matharu, M., Millen, B. A., Ossipov, M. H., Kim, B., & Yang, J. Y. (2018). Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia, 38(8), 1442-1454. https://doi.org/10.1177/0333102418779543

Chicago Style (17th ed.) Citation

Skljarevski, Vladimir, Manjit Matharu, Brian A. Millen, Michael H. Ossipov, Byung-Kun Kim, and Jyun Yan Yang. "Efficacy and Safety of Galcanezumab for the Prevention of Episodic Migraine: Results of the EVOLVE-2 Phase 3 Randomized Controlled Clinical Trial." Cephalalgia 38, no. 8 (2018): 1442-1454. https://doi.org/10.1177/0333102418779543.

MLA (9th ed.) Citation

Skljarevski, Vladimir, et al. "Efficacy and Safety of Galcanezumab for the Prevention of Episodic Migraine: Results of the EVOLVE-2 Phase 3 Randomized Controlled Clinical Trial." Cephalalgia, vol. 38, no. 8, 2018, pp. 1442-1454, https://doi.org/10.1177/0333102418779543.